MARKET

GENE

GENE

Genetic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.540
+0.380
+9.13%
After Hours: 4.540 0 0.00% 19:43 06/11 EDT
OPEN
4.760
PREV CLOSE
4.160
HIGH
5.15
LOW
4.230
VOLUME
7.90M
TURNOVER
--
52 WEEK HIGH
10.30
52 WEEK LOW
1.970
MARKET CAP
68.19M
P/E (TTM)
-8.9265
1D
5D
1M
3M
1Y
5Y
Cannabis Stock Gainers And Losers From June 11, 2021
GAINERS: CURE Pharmaceutical Hldg (OTC: CURR) shares closed up 12.33% at $0.82
Benzinga · 2d ago
Genetic Technologies (GENE) secures U.S. patent for genomic analysis; shares surge 12%
Genetic Technologies (GENE) has been granted US Patent No. 11,031,098 – ‘Computer Systems and Methods for Genomic Analysis’.GENE shares rise 12% premarket trading at $4.66.The patent describes efficient methods for identifying variations
Seekingalpha · 2d ago
US Patent Office Grants Foundational Pharmacogenomic Patent
MELBOURNE, Australia, June 11, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, has been granted US Patent No. 11,031,098 – ‘Computer System...
GlobeNewswire · 2d ago
Genetic Technologies Granted US Patent for Systems, Methods for Genomic Analysis
MT Newswires · 2d ago
Trxade, ProPhase Labs leads healthcare gainers; Aethlon Medical, Ocugen among major losers
Gainers: Trxade (MEDS) +100%, Reneo Pharmaceuticals (RPHM) +13%, ProPhase Labs (PRPH) +18%, Verona Pharma (VRNA) +13%, Myomo (MYO) +8%.Losers: Aethlon Medical (AEMD) -28%, Ocugen (OCGN) -23%, Ra Medical Systems (RMED) -16%, SCWorx (WORX) -12%, Genetic Tech...
Seekingalpha · 3d ago
Infinity Biologix launches Genetic Technologies' COVID-19 test
Infinity BiologiX announces the launch of a new test, developed by Genetic Technologies ([[GENE]] +25.7%), meant to assess the severity of COVID-19 in individuals.The availability of the test in the U.S. is a collaboration
Seekingalpha · 4d ago
Infinity BiologiX, Genetic Technologies And Vault Heath Launch New Test To Assess Severity Of COVID-19 In Individuals
Test improves COVID-19 prevention and management capabilities for employers, governments, and public health decision makers Today, Infinity BiologiX (IBX) announces the launch of a new test meant to assess the severity
Benzinga · 4d ago
Infinity BiologiX to Market Test From Genetic Technologies Assessing COVID-19 Risks
MT Newswires · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GENE. Analyze the recent business situations of Genetic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 25
Institutional Holdings: 425.99K
% Owned: 2.84%
Shares Outstanding: 15.02M
TypeInstitutionsShares
Increased
5
124.34K
New
5
65.71K
Decreased
2
9.82K
Sold Out
3
21.93K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+0.43%
Healthcare Providers & Services
-0.09%
Key Executives
Chairman/Director
Peter Rubenstein
Chief Executive Officer
George Muchnicki
Chief Executive Officer
Simon Morriss
Chief Financial Officer
Phillip Hains
Corporate Executive
Mark Ostrowski
Chief Operating Officer
Stan Sack
Executive Director
Jerzy Muchnicki
Other
Richard Allman
Other
M. Luisa Ashdown
Other
Susan Gross
Other
Diana Newport
Secretary
Justyn Stedwell
Non-Executive Director
Nick Burrows
Non-Executive Independent Director
Lindsay Wakefield
No Data
About GENE
Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.

Webull offers kinds of Genetic Technologies Limited (ADR) stock information, including NASDAQ:GENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GENE stock methods without spending real money on the virtual paper trading platform.